NEW DELHI : As the world moves into the next stage of COVID-19 management and several vaccine candidates approach end-stage trials, scientists say a critical consideration for India is storage temperature and a protein-based preventive might therefore work best for the country.The decision on procuring the right COVID-19 vaccine depends on multiple factors, including safety, price and ease of deployment, the scientists added, pitching for a preventive like the one being developed by US firm Novavax that can be stored at higher temperatures rather than those developed from mRNA or viral vectors.That would potentially rule out the three vaccine candidates that have shown over 90% efficiency over the last few days -- Pfizer-BioNtech with 90%.